Camber Capital Management LP Sarepta Therapeutics, Inc. Transaction History

Camber Capital Management LP

$3.15 Billion
Q3 2024

A detailed history of Camber Capital Management LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Camber Capital Management LP holds 775,000 shares of SRPT stock, worth $81 Million. This represents 3.07% of its overall portfolio holdings.

Number of Shares

775,000

Previous 150,000 416.67%

Holding current value

$81 Million

Previous $23.7 Million 308.4%

% of portfolio

3.07%

Previous 0.66%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $77.7 Million - $98 Million	625,000 Added 416.67%	775,000 $96.8 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $49.3 Million - $71.3 Million	-435,000 Reduced 74.36%	150,000 $23.7 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $20.1 Million - $30.4 Million	-215,000 Reduced 26.88%	585,000 $75.7 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $41 Million - $49.4 Million	400,000 Added 100.0%	800,000 $97 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $37.2 Million - $55 Million	-350,000 Reduced 46.67%	400,000 $45.8 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $58.8 Million - $78 Million	-500,000 Reduced 40.0%	750,000 $103 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $25.2 Million - $33 Million	-250,000 Reduced 16.67%	1,250,000 $162 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $26.5 Million - $41.7 Million	-350,000 Reduced 18.92%	1,500,000 $166 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $29.8 Million - $42 Million	475,000 Added 34.55%	1,850,000 $139 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $34.7 Million - $49.7 Million	550,000 Added 66.67%	1,375,000 $107 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $25.1 Million - $32.3 Million	325,000 Added 65.0%	825,000 $74.3 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $33 Million - $46.2 Million	500,000 New	500,000 $46.2 Million
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $28.9 Million - $67.6 Million	-400,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $3.14 Million - $4.47 Million	-25,000 Reduced 5.88%	400,000 $68.2 Million
Q3 2020 Nov 16, 2020	BUY	$127.12 - $172.34 $3.18 Million - $4.31 Million	25,000 Added 6.25%	425,000 $59.7 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $30.2 Million - $55.8 Million	-325,000 Reduced 44.83%	400,000 $64.1 Million
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $10.3 Million - $16.5 Million	125,000 Added 20.83%	725,000 $70.9 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $11.5 Million - $20.3 Million	-150,000 Reduced 20.0%	600,000 $77.4 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $18.2 Million - $39.2 Million	250,000 Added 50.0%	750,000 $56.5 Million
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $16 Million - $22.8 Million	150,000 Added 42.86%	500,000 $59.6 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $34.1 Million - $52.1 Million	350,000 New	350,000 $38.2 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $16.2 Million - $24.7 Million	-300,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $52.4 Million - $62.4 Million	-1,100,000 Reduced 78.57%	300,000 $16.7 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $50 Million - $66 Million	1,400,000	1,400,000 $63.5 Million

Others Institutions Holding SRPT

# of Institutions

532

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.15B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Camber Capital Management LP with notifications on news.

Account

Camber Capital Management LP Sarepta Therapeutics, Inc. Transaction History